The 12 Hallmarks of Aging in Dogs, Explained
Read full insightRapamycin for Dogs
What the trials found, what can go wrong, what it costs, and how it compares with Loyal's longevity drugs.
As Seen On
Contents
Rapamycin for dogs at a glance
- What it is
- A prescription human drug that dampens mTOR, used off-label in dogs
- Does it extend dogs' lives?
- Unknown; no finished study has measured it
- Biggest trial
- TRIAD: a planned 580 dogs, weekly for a year, followed for at least three years
- Side effects so far
- Few in small, short trials; one case of severe high triglycerides
- Research dose
- 0.15 mg/kg once a week in TRIAD, with screening and monitoring
- Cost
- About $40 to $245 for 30 tablets (GoodRx, 2025), plus exams and bloodwork
- How to get it
- Only through a vet's prescription
What the dog studies found
| Study | Dogs | Regimen | What it found |
|---|---|---|---|
| Urfer, 2017 | 24 healthy, middle-aged | 0.05 or 0.1 mg/kg, 3 times a week, 10 weeks | No more side effects than placebo; heart ultrasound suggested improvement |
| Barnett, 2023 | 17 healthy, aged 6 to 10 | 0.025 mg/kg, 3 times a week, 6 months | No heart difference; no clinically significant adverse events |
| LeBlanc, 2021 | 324 with bone cancer | Added to amputation and chemotherapy | No improvement in time to spread or in survival |
| TRIAD, running | 580 planned, healthy, aged 7+ | 0.15 mg/kg, once a week, 12 months | Measuring lifespan and health; no results yet |
Competitor label and pricing facts checked November 6, 2026. Sources are listed in the References section below.
Sources and further detail
- Coleman AE, Creevy KE, Anderson R et al. *GeroScience* (2025). Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale
- Ryave J, Coleman A. *Journal of Veterinary Science* (2025). Rapamycin as a potential intervention to promote longevity and extend healthspan in companion dogs
- Urfer SR, Kaeberlein TL, Mailheau S et al. *GeroScience* (2017). A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs
- Barnett BG, Wesselowski SR, Gordon SG et al. *Frontiers in Veterinary Science* (2023). A masked, placebo-controlled, randomized clinical trial of low-dose rapamycin in 17 healthy client-owned dogs
- Dog Aging Project, *Can I give my dog rapamycin on my own?*
- Evans JB, Chou L, Kaeberlein M et al. *Frontiers in Veterinary Science* (2023). Case report: severe asymptomatic hypertriglyceridemia with long-term low-dose rapamycin in a Labrador retriever
- Dog Aging Project, *Is it too late to sign my dog up for TRIAD?* (updated 28 Sept 2026)
- Tufts Cummings School of Veterinary Medicine, *Dog Aging Project: test of rapamycin in aging dogs (TRIAD)*
- Larson JC, Allstadt SD, Fan TM et al. *American Journal of Veterinary Research* (2016). Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs
- GoodRx (7 Aug 2025), Upcoming antiaging drugs for dogs: what you need to know
- Helping Pets Live Longer, *Rapamycin for dogs* (listed price, checked November 2026)
- FDA, *The ins and outs of extra-label drug use in animals: a resource for veterinarians*
- LeBlanc AK, Mazcko CN, Cherukuri A et al. *Clinical Cancer Research* (2021). Adjuvant sirolimus does not improve outcome in pet dogs receiving standard-of-care therapy for appendicular osteosarcoma: a randomized trial of 324 dogs
- FDA (14 March 2025), FDA conditionally approves drug for management of ventricular hypertrophy in cats
- FDA, *Conditional approval explained: a resource for veterinarians*
- Kealy RD, Lawler DF, Ballam JM et al. *JAVMA* (2002). Effects of diet restriction on life span and age-related changes in dogs











